Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $130K invested in Sonnet BioTherapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
4,287% more capital invested
Capital invested by funds: $2.97K → $130K (+$127K)
350% more funds holding
Funds holding: 2 → 9 (+7)
2.95% more ownership
Funds ownership: 0.01% → 2.96% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$138K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$83.8K |
| 3 |
Two Sigma Investments
New York
|
+$67K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$20K |
| 5 |
CWA
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
|
+$112 |
Top Sellers
SONN Hedge Fund Activity: Q4 2024 in Review
9 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2024, worth a combined $130K — up 4,287% from $2.97K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SONN positions and 0 closed out — a net gain of 7 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $138K.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $130K of Sonnet BioTherapeutics stock for Q4 2024, up 4,287% quarter-over-quarter.
- 7 funds opened new Sonnet BioTherapeutics positions in Q4 2024 and 0 closed out, a net change of +7 holders.
- The largest Sonnet BioTherapeutics buyer in Q4 2024 was Virtu Financial, an estimated $138K added.
Based on aggregated 13F filings for Q4 2024.